On the other hand, patients with ICS showed a trend towards lower inpatient costs (−100€/year), which was, however, not statistically significant.
← all excerpts
Treatment of COPD Groups GOLD A and B with Inhaled Corticosteroids in the COSYCONET Cohort - Determinants and Consequences.
1
—
—